Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Orchestra Biomed Hldgs Inc (OBIO)

Orchestra Biomed Hldgs Inc (OBIO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 251,834
  • Shares Outstanding, K 56,465
  • Annual Sales, $ 2,640 K
  • Annual Income, $ -61,020 K
  • EBIT $ -75 M
  • EBITDA $ -75 M
  • 60-Month Beta 0.63
  • Price/Sales 66.11
  • Price/Cash Flow N/A
  • Price/Book 5.53

Options Overview Details

View History
  • Implied Volatility 105.65% (-39.30%)
  • Historical Volatility 64.05%
  • IV Percentile 6%
  • IV Rank 12.61%
  • IV High 837.55% on 12/18/25
  • IV Low 0.00% on 09/05/25
  • Expected Move (DTE 1) 0.43 (10.12%)
  • Put/Call Vol Ratio 999.99
  • Today's Volume 1
  • Volume Avg (30-Day) 61
  • Put/Call OI Ratio 0.10
  • Today's Open Interest 4,154
  • Open Int (30-Day) 3,767
  • Expected Range 3.78 to 4.63

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.38
  • Number of Estimates 4
  • High Estimate -0.34
  • Low Estimate -0.42
  • Prior Year -0.43
  • Growth Rate Est. (year over year) +11.63%

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.97 +5.42%
on 12/30/25
4.99 -16.22%
on 01/09/26
-0.12 (-2.67%)
since 12/15/25
3-Month
3.26 +28.37%
on 10/17/25
5.42 -22.84%
on 11/26/25
+0.52 (+14.34%)
since 10/15/25
52-Week
2.20 +90.23%
on 09/24/25
6.16 -32.06%
on 02/05/25
-1.34 (-24.18%)
since 01/15/25

Most Recent Stories

More News
Orchestra BioMed to Receive Up to $21 Million in Proceeds from Acquisition of Vivasure by Haemonetics

$11 million in proceeds expected to be received during 2026, with remainder of expected proceeds to be received in future revenue earnouts Vivasure Medical Limited (“Vivasure”) has been a strategic...

OBIO : 4.15 (-6.95%)
HAE : 74.28 (-1.91%)
Orchestra BioMed Announces AVIM Therapy and Virtue SAB Program Presentations at ICI Meeting

Joint presentation by Orchestra BioMed and Medtronic leadership to discuss ongoing strategic collaboration for development and commercialization of AVIM Therapy for treatment of uncontrolled hypertension...

MDT : 98.68 (-0.06%)
OBIO : 4.15 (-6.95%)
Orchestra BioMed Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

NEW HOPE, Pa., Nov. 26, 2025 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) (“Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies...

OBIO : 4.15 (-6.95%)
Orchestra BioMed to Participate in Upcoming Institutional Investor Conferences

NEW HOPE, Pa., Nov. 11, 2025 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) (“Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies...

OBIO : 4.15 (-6.95%)
Orchestra BioMed Reports Third Quarter 2025 Financial Results and Highlights Recent Business Updates

Secured $147.6 million in proceeds and committed capital following completion of strategic transactions and concurrent public and private equity offerings, led by $71.6 million in committed capital from...

LGND : 195.54 (-0.51%)
MDT : 98.68 (-0.06%)
OBIO : 4.15 (-6.95%)
Orchestra BioMed to Host Business Update Call on November 12, 2025

NEW HOPE, Pa., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) (“Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies...

OBIO : 4.15 (-6.95%)
Orchestra BioMed and Terumo Enter into New $30 Million Virtue SAB Strategic Agreements

New agreement grants Terumo Virtue SAB coronary indication right of first refusal and supersedes prior distribution agreement Terumo to pay a total of $30 million to Orchestra BioMed Orchestra BioMed...

OBIO : 4.15 (-6.95%)
Orchestra BioMed Announces First Patients Enrolled in Virtue® SAB US Pivotal IDE Coronary Trial

Orchestra BioMed’s Virtue ® Sirolimus AngioInfusion TM Balloon (“Virtue SAB”) is the first non-coated drug-eluting balloon system designed to deliver a large liquid dose of proprietary extended-release...

OBIO : 4.15 (-6.95%)
Orchestra BioMed to Showcase Transformative Potential of AVIM Therapy in Keynote Presentation on Hypertensive Heart Disease at Georgia Innovation Summit

Presentation to provide comprehensive overview of AVIM Therapy clinical evidence demonstrating the potential to halt the progression of hypertensive heart disease Orchestra BioMed and Medtronic (NYSE:...

MDT : 98.68 (-0.06%)
OBIO : 4.15 (-6.95%)
Orchestra BioMed Presents New AVIM Therapy Clinical Data at HRX Demonstrating Substantial and Sustained Blood Pressure Reductions that are Reproducible Upon Reactivation Following Washout

Results from long-term follow up of patients treated with atrioventricular interval modulation (“AVIM”) therapy show blood pressure-lowering effects are sustained for years after activation, reversible...

MDT : 98.68 (-0.06%)
OBIO : 4.15 (-6.95%)

Business Summary

Orchestra BioMed Inc. is a biomedical company accelerating high-impact technologies to patients. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy(TM)for the treatment of hypertension and Virtue(R) Sirolimus AngioInfusion(TM) Balloon for the treatment of atherosclerotic...

See More

Key Turning Points

3rd Resistance Point 4.77
2nd Resistance Point 4.64
1st Resistance Point 4.55
Last Price 4.15
1st Support Level 4.33
2nd Support Level 4.20
3rd Support Level 4.11

See More

52-Week High 6.16
Fibonacci 61.8% 4.65
Fibonacci 50% 4.18
Last Price 4.15
Fibonacci 38.2% 3.71
52-Week Low 2.20

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar